Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04870814
Other study ID # 2020PPRC05
Secondary ID 2021-A00049-32
Status Completed
Phase N/A
First received
Last updated
Start date May 28, 2021
Est. completion date June 14, 2021

Study information

Verified date July 2021
Source Direction Centrale du Service de Santé des Armées
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bleeding remains the leading cause of death in combat, and the literature suggests that tourniquetable hemorrhage is the second leading cause of preventable death, behind non- tourniquetable hemorrhage. Currently, most Western armed forces recommend the use of the tactical tourniquet in combat for the management of tourniquetable hemorrhage. The SOFTT® tourniquet (Tactical Medical Solutions, Anderson) is the tactical tourniquet currently in use by the French armed forces. As the contract will soon come to an end, the question of its renewal arises. The purpose of this study is to compare 4 commercially available tactical tourniquets in healthy volunteers. The hypothesis of the research is that one of the 4 tourniquets compared is faster to set up than the others.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date June 14, 2021
Est. primary completion date June 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years; - Student of the Military Health School of Lyon Bron (Ecoles Militaires de Santé de Lyon Bron; EMSLB); - Periodic medical examination up to date with the mention "fitness for duty"; - Holder of the "Combat Rescue Level 1" training. Exclusion Criteria: - Vascular pathology; - Current progressive pathology of any kind; - History of thrombo-embolic disease; - Presence of cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking > 1 cigarette/day, BMI > 25); - Iliofemoral and axillary vascular abnormalities detected by systematic Doppler ultrasound; - Presence of symptoms suggestive of COVID-19; - Positive COVID-19 antigen test; - In contact with a person diagnosed positive for COVID-19 within 15 days prior to inclusion; - Pregnant or breastfeeding woman.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Tactical tourniquet set up
The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
Diagnostic Test:
Medical ultrasound
The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
Other:
Questionnaire
The participants will have to fill a questionnaire assessing pain (for the "receiver"), ease of use, stability and rusticity (for the "fitter").

Locations

Country Name City State
France Hôpital d'Instruction des Armées Desgenettes Lyon

Sponsors (1)

Lead Sponsor Collaborator
Direction Centrale du Service de Santé des Armées

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time required to apply the tactical tourniquet. The tourniquet application time, in seconds, measured with a stopwatch. The stopwatch will be started when the fitter takes the tourniquet, pre-positioned in a tourniquet pouch on his bullet vest.
The stopwatch will be stopped as soon as at least one of the following conditions is verified
the fitter judges the fitting to be effective
the fitter cannot tighten any more (technical limit)
the tourniquet is too painful for the receiver.
Each day during 4 consecutive days
Secondary Occlusion of the downstream arterial flow following after tactical tourniquet application The occlusion of the downstream arterial flow will be assessed by medical ultrasound after tactical tourniquet application Each day during 4 consecutive days
Secondary Ease of use of the tactical tourniquet The ease of use of the tactical tourniquet will be measured via a 5-point scale: "very easy", "easy", "intermediate", "hard" and "very hard". Each day during 4 consecutive days
Secondary Rusticity of the tactical tourniquet The rusticity of the tactical tourniquet will be assessed via a questionnaire: "sufficiently rustic" or "not sufficiently rustic" Each day during 4 consecutive days
Secondary Stability of the tactical tourniquet The stability of the tactical tourniquet will be assessed via a questionnaire, on a 5-point scale: "unstable", "not very stable", "moderately stable", "stable" or "extremely stable". Each day during 4 consecutive days
Secondary Pain experienced by the receiver during application of the tactical tourniquet Pain experienced by the receiver during application of the tactical tourniquet, measured by a scale ranging from 0 (no pain) to 10 (most unbearable pain). Each day during 4 consecutive days
See also
  Status Clinical Trial Phase
Completed NCT02815670 - Reversal Dabigatran Anticoagulant Effect With Idarucizumab Phase 3
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Recruiting NCT02972385 - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02569606 - Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
Recruiting NCT02446730 - Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Phase 4
Completed NCT01935427 - Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume N/A
Completed NCT01955720 - Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran Phase 1
Recruiting NCT01709786 - Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage N/A
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Completed NCT01191554 - Dose-ranging Study of Tranexamic Acid in Valve Surgery N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT01085006 - The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery Phase 1/Phase 2
Completed NCT00700141 - Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil® N/A
Completed NCT00375466 - Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery. N/A
Completed NCT00147420 - RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet N/A
Completed NCT00479362 - Anticoagulant Therapy During Pacemaker Implantation Phase 4
Recruiting NCT05945680 - Tranexamic Acid in Breast Esthetic Surgery. Phase 4
Completed NCT03273322 - Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure Phase 2/Phase 3
Withdrawn NCT05672407 - The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery Phase 4